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Hepatitis C (HCV) is a serious public health issue, and it is estimated that 3% of the world’s population is infected.
Patients in hemodialysis units have an increased risk for contracting HCV, and high prevalence rates have been
found in hemodialysis units around the world. This study is aimed at determining the prevalence of HCV in patients
with terminal chronic renal disease (tCRD) who have been submitted to hemodialysis and peritoneal dialysis in
southern Brazil to characterize the most prevalent genotypes, the viral load, and possible risk factors and to assess
the validity between the ELISA and RT-PCR detection methods. Of 320 patients from three dialysis units, 318
participated in this study. According to the medical records, 55 patients were reactive to HCV, as determined via
ELISA. All 318 samples were submitted to RT-PCR and genotyped using an Abbott Realtime® m2000 system. Data
obtained through a questionnaire and chemical variables were associated with the HCV. Results: The prevalence of
HCV was 18.24% (58), and the concordance between the HCV serology and the RT-PCR was 94%. Three patients
were diagnosed to be negative for HCV using the ELISA assay but positive when using RT-PCR. Genotype 1 was the
most prevalent (46.7%) genotype, within which subtype 1a was the most frequent (74.1%). One of the risk factors
associated with HCV infection was the length of time that the patient had been undergoing hemodialysis
treatments (p < 0.001). Additionally, the viral load was found to vary when tested before and after hemodialysis
(p < 0.001). Conclusion: The prevalence of HCV in dialysis units continues to remain high, indicating nosocomial
contamination. RT-PCR detected the presence of the hepatitis C virus in patients with a non-reactive serology,
which highlights the importance of performing molecular tests on dialysis patients. The variation in the viral
load in patients submitted to hemodialysis indicates a possible destruction or gripping of viral particles to the
dialyzer membrane.* Correspondence: nayleoliveira@gmail.com
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In Brazil, between 2.5% and 4.9% of the population is in-
fected with the hepatitis C virus (HCV). In the state of
Rio Grande do Sul, the detection rate of 14.75 per 100
thousand inhabitants is considered high compared with
the national average of 6.17 per 100 thousand inhabi-
tants. This rate reflects the magnitude of the problem in
the state [1-3].
Patients in dialysis units have been shown to have a
higher risk for HCV infection compared with the preva-
lence of the antibody in groups of blood donors [3,4],
which may contribute to the nosocomial dissemination
in dialysis centers. There are several factors that are par-
ticularly related to the high prevalence rates, such as
blood transfusions and the length of time that the pa-
tient has been undergoing hemodialysis [5,6].
According to the 2012 Census of the Brazilian Society
of Nephrology, Brazil has an estimated 97,586 patients
undergoing dialysis treatments, and the prevalence rate
continues to increase [7]. Brazil is a continent-sized
country, and although the prevalence of HCV among
hemodialysis patients is known, with rates varying from
8.4% to 39.2%, the genotyping is not well documented
[8]. Genotype 1 is predominant among hemodialyzed pa-
tients, and subtype 1a is the most frequently identified
subtype, followed by 1b and 3a [8-10]. Two studies, one
from Belo Horizonte, MG and a more recent study from
Rio Grande/RS, showed that subtype 2b is the second
most prevalent subtype [11,12].
The ELISA method (Enzyme-Linked Immunosorbent
Assay), which is highly sensitive and specific, is used for
the diagnosis and antibody screening of HCV in he-
modialysis patients. However, patients with terminal
chronic renal disease (tCRD) who are undergoing dialy-
sis treatments may show a decrease in humoral and
cellular immunity, which may lower the sensitivity of
the test and give a false-negative result. For this rea-
son, RNA-HCV detection using the RT-PCR technique
(reverse transcription polymerase chain reaction) is ne-
cessary, as it detects small quantities of the virus in the
bloodstream, dismissing any false-negative results and
confirming the HCV diagnosis in these patients [13,14].
The analysis of the nucleotide sequence amplified using
PCR followed by a phylogenetic analysis is the gold
standard technique for detecting and identifying the
genotypes and subtypes of HCV [15,16]. The most fre-
quently used regions for sequencing are the 5′-UTR and
the NS5b regions [14].
This study is aimed at determining, via RT-PCR, the
prevalence of the hepatitis C virus among hemodialysis
patients, the possible associated risk factors and the vari-
ation in the number of viral particles during hemo-
dialysis in patients with tCRD from three dialysis units
located in a municipality in southern Brazil.Patients and methods
Target-population
The target population included patients who underwent
dialysis in any of the three renal replacement therapy
units in the city of Pelotas, RS, between March 2012 and
August 2013. Of 320 patients, 318 signed the free and in-
formed consent form, responded to a sociodemographic
and behavioral questionnaire, and submitted a 5-milliliter
sample of venous blood. Additionally, the biochemical
variables from the same month were obtained from each
interviewee’s medical record. The study was approved
by the Health Research Ethics Committee, Plataforma
Brasil on May 17, 2012 (http://aplicacao.saude.gov.br/
plataformabrasil/login.jsf ), with the decision number
23403 and the CAAE number 01902112.7.0000.5339.
Detection, genotyping and the RNA-HCV viral load
A 5 mL sample of blood was collected before hemo-
dialysis session using a vacuum tube containing EDTA
(ethylenediaminetetraacetic acid) and was immediately
centrifuged. A sample of blood was collected before and
after hemodialysis session for identification of RNA-HCV
viral load. The plasma was separated, and the sample was
stored at -70°C until the analysis. The samples were sub-
mitted to molecular diagnosis (qualitative RNA-HCV test
using RT-PCR) at the Molecular Biology Lab at FURG,
Rio Grande. First, the viral RNA was extracted from a
140-μL sample of plasma using the QIAamp®Viral RNA
kit (Qiagen lnc., Chatsworth, CA, USA). Following the ex-
traction, the viral RNA was resuspended to a final volume
of 10 μL in DEPC water containing 150 ng/μL of random
primers (Life Technologies, Carlsbad, USA) and was incu-
bated for 10 minutes at 70°C. The reverse transcription
was carried out using 200 U of Moloney Murine Leukemia
Virus Reverse Transcriptase (M-MLV RT) (Invitrogen),
0.1 M DTT, 25 U of RNaseOUT™ (Life Technologies) and
0.5 mM of each dideoxynucleotide (dATP, dTTP, dCTP,
dGTP) for 90 minutes at 37°C in a thermocycler. To
amplify a fragment from the 5′-UTR region of the HCV
genome, the following initiators were used: NCR2 forward
(5′-ATACTCGAGGTGCACGGTCTACGAGACCT-3′)
and PTC1 reverse (5′-CGTTAGTATGAGTGTCGTGC-3′)
for the first round of amplification and PTC3 forward
(5′-GTGTCGTGCAGCCTCCAGG-3′) and NCR4 re-
verse (5′-CACTCTCGAGCACCCTATCAGGCAGT-3′)
for the second round of amplification, according to Cam-
piotto et al. [17]. The following initiators were used for
NS5B region: PR3 (5′-TATGAYACCCGCTGYTTTGA
CTC-3′) and PR4 (5′-GCNGARTAYCTVGTCATAGCC
TC-3′) for the first round of amplification and PR5 (5′-
GCTAGTCATAGCCTCCGT-3′) and PR3 for the second
round of amplification, according to Sandres-Sauné et al.,
[18]. A 225-bp fragment was obtained from the 5′-UTR
region, and a 382-bp fragment was obtained from the
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violet light after electrophoresis in a 2% agarose gel
stained with ethidium bromide. Genotyping and viral load:
the samples were genotyped using an Abbott Realtime®
m2000 system in the CD4 and viral load lab of HU-FURG
(Federal University of Rio Grande). Variables in the out-
come: The independent variables that were analyzed were
age, sex, level of education, complexion, marital status,
blood transfusion, health care professional, use of inject-
able drugs, use of inhaled cocaine, sharing of syringes,
surgical procedures, presence of tattoos or piercings, and
presence of sexually transmitted diseases (STDs). The out-
come or dependent variable was the presence of an HCV
infection, confirmed via RT-PCR, the genotype and the
viral load of each patient.
Statistical analysis
The statistical analyses were carried out using STATA
software, version 12.1 (StataCorp, Texas). In the descrip-
tive analyses, percentages were used for the categorical
variables; the mean and standard deviation were used for
the symmetric quantitative variables; and the median
and interquartile range were used for the asymmetric
variables. In the bivariate analyses, a χ2 (chi-squared)
test and Fischer’s exact test were used to test the diffe-
rences in the categorical variables, and the t-test or the
Wilcoxon test was used for the continuous variables. In
the multivariate analyses, a backward Poisson regression
was used to assess the independent effect of the vari-
ables, and the prevalence ratios and their respective
robust 95% confidence intervals were calculated. The
Wald test was used as a statistical test. The statistical
significance cut-off point was p < 0.05.
Results
Of the 318 patients who agreed to participate in this study,
287 (90.25%) were undergoing hemodialysis, and 31
(9.75%) were undergoing peritoneal dialysis. The 3 three
surveyed clinics were referred to as Clinic 1, 2 or 3. All of
the patients in “Clinic 1” came from the Single Health
System (SUS), and 103 patients were interviewed. In
“Clinic 2”, 100% of the patients were from the SUS, and
98 patients were interviewed. At “Clinic 3”, 90% of its pa-
tients came from the SUS, 10% came from private health
plans, and 107 patients were interviewed. When looking
at the types of renal replacement therapy (hemodialysis
and peritoneal dialysis), 60% of the patients at “Clinic 1”
were undergoing peritoneal dialysis, while “Clinic 2” had
3%, and “Clinic 3” had 4%. The prevalence of HCV in the
patients from the three surveyed hemodialysis units was
18.24% (Clinic 1 had 18, Clinic 2 had 31 patients and
Clinic 3 had 9 patients HCV-positive). Among those who
had HCV, 51.7% were male, 55.2% did not have a partner,
and their average age was 59.3 years (dp ± 16). The mostprevalent group in terms of education level was the
illiterate group (79.3%), and none of the HCV-reactive pa-
tients had a higher education degree. In terms of blood
transfusion, 79.3% of the patients said they had received
blood at least once in their lives. When asked about the
use of condoms in different types of relationships (long-
term or occasional partner), 65.5% of the patients said
they had never used condoms. When analyzing the pre-
sence of the virus between the two types of dialysis, three
categories emerged: category A: those who had always
undergone hemodialysis; category B: those who had only
undergone peritoneal dialysis; and category C: those who
had undergone hemodialysis before starting peritoneal
dialysis. Among all of the patients, 18.7% of the patients
from category A and 8.6% from category C were found to
be positive for HCV, while no patients from category B
were found to have the virus.
In regards to the hemodialysis location, “Clinic 1”
showed statistical significance in the gross analysis as well
as the adjusted analysis (p < 0.001) and therefore offered a
higher risk for HCV. The average duration of hemodialysis
treatments among the 58 HCV-infected patients in this
study was 101.6 months (dp ± 80.6), while the average dur-
ation for peritoneal dialysis was 5.4 months (dp ± 19.7).
Based on the results of the model of logistic regression
analyzing up the hemodialysis time, it is estimated that
every year the HD patients has 6.7 times more likely to
HCV infection. This shows a significant difference bet-
ween the duration of therapy and the two types of dialysis
treatments that were performed (p < 0.001) (Table 1).
An adjusted analysis was performed by simultaneously
adjusting the risk behaviors and the presence of STD.
The prevalence of HBV among the patients was 2.6%,
while HIV was 1%. A Poisson regression with a robust
variance was also performed, and the presence of STD
lost significance following the adjustment, but the co-
infection with HBV remained significant (p < 0.006). The
use of injectable drugs, a variable that was not significant
in the gross analysis, became significant (p < 0.037) fol-
lowing the adjustment (Table 2).
The biochemical variables were obtained via medical
records. The means and standard deviations of the sym-
metric variables were calculated according to the HCV
results, and the p value indicates that the analyzed
values are different between the HCV-positive and
HCV-negative individuals. For the alanine transaminase
(ALT), glucose and creatinine analysis, a non-parametric
test (Wilcoxon) was performed for the asymmetric vari-
ables. For this reason, the description was made using
the median value and the interquartile range (25th and
75th percentiles).
Among the samples sent for genotyping (n = 58), 81.03%
(47) were genotyped because they were above the mini-
mum detection limit (<12 IU/mL). Abbott®’s real-time
Table 1 Prevalence ratios and confidence intervals (CI 95%) between the presence of reactive HCV and the risk factors
surveyed (n = 318)
N % PR CI 95% p-value* PR CI 95% p-value*
Sex 0.559 0.458
Female 28 20.0 Ref. (1) - Ref. (1) -
Male 30 16.9 0.84 0.52; 1.34 0.84 0.53; 1.32
Complexion 0.411 0.777
White 40 17.1 Ref.(1) - Ref. (1) -
Not white 18 21.4 1.25 0.76; 2.06 1.07 0.65; 1.81
Age (years) 0.081 0.085
Up to 59 35 22.3 Ref. (1) - Ref. (1) -
60 or older 23 14.3 0,64 0.39; 1.03 0,66 0.41; 1.05
Level of education 0.407 0.117
Illiterate 46 19.7 Ref. (1) - Ref. (1) -
Incomplete or complete Primary School 12 14.6 0.74 0.41; 1.33 0.71 0.46; 1.09
Marital status 0.772 0.721
Without partner 32 19.1 Ref. (1) - Ref. (1) -
With partner 26 17.3 0.91 0.59; 1.45 0.91 0.57; 1.45
Hospital 0,003† 0.001
Clinic 1 18 17.5 Ref. (1) - Ref. (1) -
Clinic 2 31 31.6 1.81 1.01; 3.24 1.54 0.90; 2.62
Clinic 3 9 7.9 0.45 0.21; 0.98 0.44 0.20; 0.94
HD e PD 0.063†
Only HD 53 18.7 Ref. (1) - Ref. (1) - 0.653
Only DP - - - - - -
HD and then PD 5 27.8 1.48 0.59; 3.70 1.19 0.55; 2.58
*PR: prevalence rate.
†Wald Test.
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6 and subtypes a and b using a serum volume of 0.5 ml
or 0.2 ml. The test’s sensitivity is ≥500 IU/mL, and its
specificity is 97.0%. The quantification of RNA-HCV on
the Abbott Realtime® m2000 system has a sensitivity of
12 IU/mL for a 0.5-ml sample, with a specificity of ≥99.5%.
Genotype 1 was the most prevalent (46.7%), followed by
genotype 3 (19.0%) and genotype 2 (5.3%). Genotypes 4, 5
and 6 were not identified. Within genotype 1, subtype 1a
was the most the prevalent (74.1%), followed by subtype
1b (11.1%). In regards to the distribution of the genotypes
among the hospitals, subtype 1a was the most prevalent in
all three hospitals.
The viral load values were also analyzed, and sta-
tistically significant differences (p < 0.001) between the
viral load values before and after the hemodialysis ses-
sions were observed (Table 1). When the difference was
analyzed by genotype, a significant difference (p < 0.001)
was also observed between the viral loads (Table 3).
Among the studied individuals, three patients who had
negative results according to the ELISA antibody surveyshowed positive RNA detection via the molecular tests,
which shows 94% of concordance between the tests.
RT-PCR has a higher sensitivity when compared to ELISA.
Discussion
This is the first study to verify the prevalence, genotypes,
viral load and risk factors connected with HCV infection
in patients from dialysis units in the city of Pelotas in
southern Brazil. The infection caused by this virus is still
an ongoing problem in renal replacement therapy units.
Currently, the hepatitis C virus is the most frequently
found in patients with terminal chronic renal disease
(tCRD) undergoing hemodialysis treatments. In Brazil,
the number of patients undergoing dialysis treatments
has been rapidly increasing, with an estimated 34,366
new cases every year [19], which includes an estimated
5,963 new cases in the southern part of the country [19].
These numbers highlight the grave problem that HCV
represents in dialysis units, as dialysis units represent
one of the main risk groups for HCV infection. The
results show a continued high prevalence (18.24%) of
Table 2 Prevalence ratios and 95% confidence intervals between the presence of reactive HCV, the factors investigated
and the behavioral data in the patients from Pelotas (n = 318)
N % PR CI 95% p-value* PRA CI 95% p-value
Health Professional 0.712 -
No 55 18.0 Ref. (1) - - -
Yes 3 23.1 1.28 0.46; 3.55 - -
Blood transfusion 0.732 -
No 12 16.2 Ref.(1) - - -
Yes 46 18.9 1.16 0.65; 2.01 - -
Use of injectable drugs 0.153 0.037
No 56 17.8 Ref. (1) - Ref. (1) -
Yes 2 50.0 2.8 1.02; 7.69 4.16 1.08; 15.9
Syringe sharing 0.998 0.587
No 52 18.4 Ref. (1) - Ref. (1) -
Yes 6 17.1 0.93 0.43; 2.00 0.76 0.31; 2.06
Inhaled cocaine 0.998 0.381
No 57 18.3 Ref. (1) - Ref. (1) -
Yes 1 16.7 0.90 0.14; 5.53 0.51 0.12; 2.24
Tattoo, piercing, acupuncture 0.438 0.300
No 12 18.8 Ref. (1) - Ref. (1) -
Yes 46 11.5 0.61 0.21; 1.82 0.56 0.18; 1.67
HIV 0.332 0.184
No 57 18,1 Ref. (1) - Ref. (1)
Yes 1 50.0 2.76 0.67; 9.23 2.35 0.85; 6.44
HBV 0.006 <0.001
No 53 17.0 Ref. (1) - Ref. (1)
Yes 5 62.5 3.65 2.02; 6.59 3.41 1.82; 6.38
STD in the past year 0.049 0.098
No 45 16.4 Ref. (1) - Ref. (1)
Yes 13 29.5 1.80 1.06; 3.05 1.48 0.83; 2.65
Use of condom long-term partner 0.416† 0.452
Never 38 16.6 Ref. (1) - Ref. (1)
Always 6 17.6 1.06 0.45; 2.51 1.08 0.34; 3.40
Sometimes 14 25.5 1.53 0.83; 2.83 2.07 0.59; 7.17
Use of condom occasional partner 0.673† 0.723
Never 38 16.9 Ref. (1) Ref. (1)
Always 6 20.0 1.18 0.50; 2.80 0.99 0.29; 3.37
Sometimes 14 22.2 1.32 0.71; 2.43 0.66 0.19; 2.24
*PR: prevalence rate.
†Wald Test.
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advances in the techniques for detecting and preventing
HCV, in addition to HCV education.
It is believed that the viral transmission may originate
from several factors: surgeries and transfusions, to which
the patients are often submitted, and biosafety factors,
such as an unprepared technical team and the improperuse of equipment for HCV-positive patients, which
should be used exclusively by the infected patients. It
may also be associated with the hemodialysis procedure
itself (horizontal transmission), dermal transmission
through aerosol or droplets during fistula cannulation,
dialysis accidents involving blood spillage or transmis-
sion via contact with equipment used by contaminated
Table 3 Viral load (number of copies of HCV-RNA per mL of plasma) for each HCV genotype in patients from in a city
in southern Brazil (n = 58)
Genotype
G1 G 2 G 3
Median Pc 25 - Pc Median Pc 25 - Pc Median Pc 25 - Pc
p-value*
(x1000) 75 (x1000) 75 (x1000) 75
Viral load before (IU/L) 467.1 165.2; 890.1 1,011.3 12.6; 3,018.1 267.9 25.8; 1,450 <0.001
Viral load after (IU/L) 376.3 12.9; 579.8 852.7 2.3; 1,676.8 1,001.3 1.7; 1,532.5 <0.001
*Only for patients undergoing hemodialysis treatment.
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HCV positivity and the location of treatment was
analyzed, the patients who received dialysis services at
“Clinic 2” showed a 54% greater chance of being infected
with HCV (p < 0.001). This situation was further con-
firmed by the adjusted analysis, revalidating the affir-
mation that this institution provides a potential risk for
HCV infection to CRD patients. Further research is still
necessary to corroborate this hypothesis.
In many developing countries, the primary method of
infection is through blood transfusions because untested
blood and blood derivatives are still used, in addition
to poorly sterilized equipment. In Brazil, however, the
implementation of triage tests in blood banks by the
Ministry of Health in 1993, through directive n. 1376,
along with the introduction of human recombinant
erythropoietin, has led to a decrease in the transmission
of the virus during transfusions [22,23]. In our study,
blood transfusions prior to 1993 were significantly asso-
ciated with the presence of HCV and were one of the
most probable causes of infection reported by patients
with HCV.
Another important factor in the transmission of HCV
is surgery. One hundred percent of the HCV-positive pa-
tients had previously undergone some type of surgery.
Surgery makes patients more prone to HCV infection
because of the possible exposure to shared materials and
the necessity for blood transfusion, especially prior to
1993 [24,25].
According to the literature data, HCV infection is asso-
ciated with the number and duration of the hemodialysis
treatments [24,26]. In this study, the length of time that
the patient had been undergoing hemodialysis treatments
was statistically significant for the HCV-positive patients
(p < 0.001), with an average of 101.6 months (dp ± 80.6),
indicating that the longer the hemodialysis permanence
time the higher the probability of contracting HCV. It is
not recommended for HCV patients to have isolation
rooms, but there should be different technical teams
to avoid any contact between HCV-positive and HCV-
negative patients, as well as a only reusing HCV rooms for
patients with hepatitis C and providing other rooms for
patients with hepatitis B [27]. The movement of thenursing team and the sanitization team and the lack of
isolation of HCV-positive patients are highly significant
factors for the transmission of the hepatitis C virus.
In addition, it must be highlighted that the dialyzer
should only be reused 12 times, according to directive
n.82/GM (2000) from the Ministry of Health [4]. All
three of the units that were assessed followed the rules
of the National Health Surveillance Agency (ANVISA)
RCD n.154 related to the reuse of dialyzers and to the
attending of patients with reactive hepatitis B and C and
HIV [28,29]. The patients and health professionals in
dialysis units must be monitored so that it can be pos-
sible to determine the real risk factors for HCV infec-
tion. To prevent infection, it is necessary to implement
quality biosafety programs in the units, ensuring that the
workers are adequately trained, and a providing a super-
visory technical team for epidemiological surveillance.
The peritoneal dialysis procedure is performed by the
own patient in his home, with disposable equipment
thus avoiding contact with infected patients, thus redu-
cing the possible transmission, justifying our results of
none patient infected with HCV in this modality.
The HCV detection method used in the surveyed dia-
lysis units is the ELISA technique. This study made use
of another molecular technique (RT-PCR) to investigate
the prevalence of individuals infected by HCV. There-
fore, we were able to compare the serological results
with the detection of the viral RNA. Several authors
have reported false-negative results in the serological
tests of patients with tCRD undergoing renal replace-
ment therapy. This highlights the importance of viral
RNA identification in such patients [8,13,14,30]. The
spread of HCV in dialysis units may be associated,
among other aspects, with the difficulty in diagnosing
the infection during the initial phase, when the serum
conversion has not yet occurred [31]. This may have
been a crucial factor for the lack of detection of the
HCV antibodies in the individuals who tested positive
for HCV via the RT-PCR methodology. In regards to
the ELISA test, hemodialyzed patients may show false-
negative results and unintentionally be exposed to pos-
sible nosocomial transmissions [13,32]. It is important to
emphasize that the patients from renal replacement
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which lowers the production of antibodies and con-
sequently creates false-negative results in their tests.
Therefore, the standard test used in these units should
be viral RNA testing via PCR. The use of RT-PCR for
the molecular diagnosis of HCV, using regions such as
the 5′ UTR and NS5b from the viral genome, is a sensi-
tive and specific methodology for the detection of the
virus [14].
The distribution of these genotypes was similar to that
found by Campiotto in a study performed using labo-
ratory samples from different locations in Brazil, with
genotype 1 being the most prevalent (64.9%), followed
by genotypes 3 (30.6%) and 2 (4.6%). It is important to
emphasize though that these samples did not solely be-
long to hemodialysis patients [17]. In a study performed
with hemodialysis patients in the city of Goiás, Espirito-
Santo identified genotypes 1a (65.7%), 1b (26.7%) and 3
(7.6%) to be the most prevalent [33]. In a study of blood
donors from Distrito Federal, Amorim et al. identified
the prevalence of genotypes 1a (82.3%), 3a (9.8%), and
1b (5.9%), followed by the co-infection of 1a/1b (2%)
[10]. In our study, co-infections of the different geno-
types were not identified. It has already been shown that
genotype 1a is found in significant percentages in Brazil
[10,33], although da Silva et al. have identified the preva-
lence of genotype 1b followed by genotype 2b [12]. Fur-
ther studies will be performed throughout southern Rio
Grande do Sul to assess the distribution of the genotypes
in dialysis units in southern Brazil.
The viral load had a significant variation when tested
before and after the hemodialysis session (p < 0.001). The
average was 44×104 IU/L (dp: 64×104) before hemo-
dialysis and 34×103 (dp: 50×104) after hemodialysis, indi-
cating the possible destruction or adherence of the viral
particles to the dialyzer membrane [34-36]. This may
mean that patients undergoing hemodialysis have a more
stable viral load when compared to those who are not
undergoing this type of treatment [37,38]. It is well known
that the HCV viral load influences the course of the anti-
viral treatment and is used to assess the virological re-
sponse. Patients with hepatitis undergoing hemodialysis
actually live longer, as there are studies showing that there
is less hepatic damage [39,40]. It was observed that geno-
type 2 had the highest viral load, 11×105 (dp: 17×105),
compared with genotypes 1 and 3. When analyzed after
the hemodialysis session, genotype 3 showed an increase
in the viral load from 69×104 (dp: 72×104) to 74×104
(dp: 71×104). These results indicate that more studies of
the viral load in relation to hemodialysis treatments are
necessary.
The average ALT level found among the patients from
the units studied was of 15.3 IU/L (dp ± 12.3). When
analyzing the values of this enzyme only in the group ofpatients with HCV, the average changed to 24.2 IU/L
(dp ± 20.6), which is significantly higher (p < 0.001) than
the average found by Fabrizi and contributors (18.9 IU/L),
in their study correlating hepatic damage with amino-
transferases and viral load during a 13-month period [34].
The mean ALT values increased when comparing the
HCV-positive and HCV-negative patients, but the values
were still within the “normal” levels (20 IU/L) [34,41]. Al-
tered ALT levels are not common in patients with HCV
undergoing hemodialysis treatments, which suggests that
aminotransferases are not good predictors of hepatocellu-
lar injury for these patients because it is believed that
there is enzymatic inhibition of the aminotransferases due
to uremic toxins, pyridoxine deficiency (cofactor of ami-
notransferases), loss of enzymes in dialysis, interference of
other dialyzable substances in the dosage of transaminase
activity and lactate consumption of the factors that are
necessary for the dosage of transaminase activity [39].
Several studies have shown that the ALT levels can be
higher in HCV-positive patients compared with HCV-
negative individuals, even when the values are below those
considered to be normal, and the aminotransferase varia-
tions are related to the HCV viral load [34,42].
Conclusion
The high prevalence of HCV in patients undergoing
hemodialysis is still a grave problem. RT-PCR is proven
to be more sensitive than the routine serological tests
performed in the clinics studied, indicating that molecu-
lar tests are a better option for patients undergoing dia-
lysis. Co-infection with HBV and the use of injectable
drugs are risk factors for HCV infection, as well as the
overall length of time that the patient has been undergo-
ing hemodialysis treatments. The variation in the viral
load when tested before and after hemodialysis showed
different values when correlated to the different viral ge-
notypes. These results show the importance of aiming
new research on this area to assess and compare the
reuse of dialyzers, and the results further indicate the
importance of single-use dialyzers as a protection factor
against HCV.
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